Nov 15, 2021 | BALTIMORE – Complete Omics’ Clinical Proteomics team announced a collaboration with Netherlands Cancer Institute on a series of quantitative phosphoproteomics projects.
The Netherlands Cancer Institute (NKI) in Amsterdam was founded in 1913 and is a combination of a scientific research institute with a specialized clinic focused on combating cancers.
The collaboration will utilize our Complete360® ultrasensitive protein detection platform for phosphoproteomica assays on a variety of samples.
